- Datum10.06.2026
- Uhrzeit12:00 - 13:00 Uhr
- Veranstalter
stock3
Autolus Therapeutics Ltd. Reg.Shs (Spons. ADRs)/1 o.N. Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate BSX | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-5,15 %
Intraday
4,17 %
1 Woche
19,05 %
1 Monat
-12,06 %
Seit Jahresbeginn
-15,46 %
1 Jahr
-39,66 %
3 Jahre
-72,04 %
5 Jahre
Passender Service zu Autolus Therapeutics Ltd. Reg.Shs (Spons. ADRs)/1 o.N.
Webinar zu Autolus Therapeutics Ltd. Reg.Shs (Spons. ADRs)/1 o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,175-2,700
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Autolus Therapeutics Ltd. Reg.Shs (Spons. ADRs)/1 o.N.
Keine Dividenden verfügbar
Termine von Autolus Therapeutics Ltd. Reg.Shs (Spons. ADRs)/1 o.N.
Keine aktuellen Termine
Beschreibung
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
